<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Genomics</journal-id><journal-id journal-id-type="iso-abbrev">Hum. Genomics</journal-id><journal-title-group><journal-title>Human Genomics</journal-title></journal-title-group><issn pub-type="ppub">1473-9542</issn><issn pub-type="epub">1479-7364</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4603341</article-id><article-id pub-id-type="publisher-id">48</article-id><article-id pub-id-type="doi">10.1186/s40246-015-0048-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Primary Research</subject></subj-group></article-categories><title-group><article-title>Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moarii</surname><given-names>Matahi</given-names></name><address><email>matahi.moarii@mines-paristech.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Reyal</surname><given-names>Fabien</given-names></name><address><email>fabien.reyal@curie.fr</email></address><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Vert</surname><given-names>Jean-Philippe</given-names></name><address><email>jean-philippe.vert@mines-paristech.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>CBIO-Centre for Computational Biology, Mines Paristech, PSL-Research University, 35 Rue Saint-Honore, Fontainebleau, F-77300 France </aff><aff id="Aff2"><label/>Department of Bioinformatics, Biostatistics and System Biology, Institut Curie, 11-13 Rue Pierre et Marie Curie, Paris, F-75248 France </aff><aff id="Aff3"><label/>U900, INSERM, 11-13 Rue Pierre et Marie Curie, Paris, F-75248 France </aff><aff id="Aff4"><label/>UMR932, Immunity and Cancer Team, Institut Curie, 26 Rue d&#x02019;Ulm, Paris, 75006 France </aff><aff id="Aff5"><label/>Department of Translational Research, Residual Tumor and Response to Treatment Team, Institut Curie, 26 Rue d&#x02019;Ulm, Paris, 75006 France </aff><aff id="Aff6"><label/>Department of Surgery, Institut Curie, 26 Rue d&#x02019;Ulm, Paris, 75006 France </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>9</volume><elocation-id>26</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Moarii et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The CpG island methylator phenotype (CIMP) was first characterized in colorectal cancer but since has been extensively studied in several other tumor types such as breast, bladder, lung, and gastric. CIMP is of clinical importance as it has been reported to be associated with prognosis or response to treatment. However, the identification of a universal molecular basis to define CIMP across tumors has remained elusive.</p></sec><sec><title>Results</title><p>We perform a genome-wide methylation analysis of over 2000 tumor samples from 5 cancer sites to assess the existence of a CIMP with common molecular basis across cancers. We then show that the CIMP phenotype is associated with specific gene expression variations. However, we do not find a common genetic signature in all tissues associated with CIMP.</p></sec><sec><title>Conclusion</title><p>Our results suggest the existence of a universal epigenetic and transcriptomic signature that defines the CIMP across several tumor types but does not indicate the existence of a common genetic signature of CIMP.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s40246-015-0048-9) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Epigenetic modifications have been recognized as important players in cancer etiology and development and constitute promising therapeutic targets for diagnosis or treatment due to their possible reversibility [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. In particular, aberrant methylation of CpG islands (CGIs) located in promoter regions of tumor suppressor and DNA repair genes, leading to their silencing, is now considered a hallmark of cancer playing an important role in neoplasia [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The CpG island methylator phenotype (CIMP) was first defined and observed by [<xref ref-type="bibr" rid="CR7">7</xref>] in a subset of colorectal cancers as the joint methylation of several promoter regions, leading to the inactivation of the corresponding genes. The stratification of patients based on CIMP was shown to be clinically relevant, as CIMP-positive patients had better prognosis than CIMP-negative ones, and could lead to personalized treatments. Since the identification of CIMP in colorectal cancers, many studies have tried to replicate the analysis to find CIMP in different types of cancers including but not limited to colon [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], breast [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], lung [<xref ref-type="bibr" rid="CR15">15</xref>], stomach [<xref ref-type="bibr" rid="CR16">16</xref>], and glioblastoma [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. While most of these works concluded in the existence of a CIMP in different cancers, other studies did not yield the same conclusions [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], and the genes whose promoter CGI methylation are considered to define the CIMP differ between studies. This raises the question of whether the CIMP is tissue specific or is a universal phenomenon with common biological causes affecting common genes across cancers. A recent review of CIMP-related studies across different cancers pointed out the diversity of methods and measurement technologies used to define CIMP, which hinders the establishment of a molecular basis for CIMP in spite of growing evidence linking mutations in specific genes and CIMP in several cancers [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>In the present study, we investigate the existence and universality of CIMP by performing a systematic genome-wide methylation analysis on several large datasets of different cancer types simultaneously. We propose a simple methodology to assess the existence of a CIMP phenotype in each cancer and to identify a set of genes whose promoter methylation is a marker for the CIMP. This allows us to compare the different cancer types in search for a cross-cancer CIMP signature and to analyze the link between CIMP and gene expression in different cancers. Finally, we assess the clinical relevance of CIMP on the overall survival.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>A cross-cancer CIMP signature</title><p>We first assess with a common methodology whether a CIMP can be detected on different cancers and whether CIMP in different cancers share a common signature in terms of which gene promoters are hypermethylated in CIMP-positive patients. For that purpose, we collected high-density methylation datasets from the cancer genome atlas (TCGA) data portal providing more than 485,000 CpG methylation levels for more than 2000 samples from five tissues of origin: bladder, breast, colon, lung, and stomach (Table <xref rid="Tab1" ref-type="table">1</xref>). For each sample, we aggregate the methylation levels of CpG probes by CGI, including the CGI itself and its shores and shelves, resulting in a single methylation level for each of 21,176 CGIs in each sample.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients&#x02019; dataset. Number of samples available for the different cancer types (first column) for methylation (Meth) and gene expression (GE). The &#x0201c;Meth/GE&#x0201d; column summarizes the number of samples with both methylation and gene expression, while the &#x0201c;Meth/Mutations&#x0201d; column shows the number of samples with both methylation and DNA mutation data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Tissue</th><th align="left">Meth</th><th align="left">GE</th><th align="left">Meth/GE</th><th align="left">Meth/Mutations</th></tr></thead><tbody><tr><td align="left">Bladder</td><td align="left">373</td><td align="left">56</td><td align="left">
<italic>43</italic>
</td><td align="left">
<italic>28</italic>
</td></tr><tr><td align="left">Breast</td><td align="left">626</td><td align="left">778</td><td align="left">
<italic>478</italic>
</td><td align="left">
<italic>468</italic>
</td></tr><tr><td align="left">Colon</td><td align="left">291</td><td align="left">193</td><td align="left">
<italic>34</italic>
</td><td align="left">
<italic>219</italic>
</td></tr><tr><td align="left">Lung</td><td align="left">452</td><td align="left">125</td><td align="left">
<italic>82</italic>
</td><td align="left">
<italic>411</italic>
</td></tr><tr><td align="left">Stomach</td><td align="left">338</td><td align="left">373</td><td align="left">
<italic>309</italic>
</td><td align="left">
<italic>199</italic>
</td></tr><tr><td align="left">Overall</td><td align="left">
<italic>2090</italic>
</td><td align="left">
<italic>1525</italic>
</td><td align="left">
<italic>941</italic>
</td><td align="left">
<italic>1325</italic>
</td></tr></tbody></table></table-wrap></p><p>A CIMP corresponds to the joint hypermethylation of a subset of CGIs in a subset of samples [<xref ref-type="bibr" rid="CR7">7</xref>]. To characterize from whole-genome methylation data whether a CIMP exists for a cancer and which CGIs characterize it, we follow a standard methodology: (i) select the 5 % most variant CGIs in the set of samples, which we call the <italic>CIMP signature</italic> and (ii) check by unsupervised classification whether the samples cluster into two main clusters (CIMP-positive and -negative clusters) when we restrict them to the methylation values they take on the CGIs in the CIMP signature.</p><p>We apply this methodology to each of the five families of tumors, cutting the tree obtained by hierarchical clustering to two clusters in order to enforce a classification of all samples into two subgroups based on the methylation of CGIs in the CIMP signature. Interestingly, in all five cases, one of the two clusters is clearly characterized by an overall hypermethylation of most CGIs in the signature compared to the second cluster, allowing us to characterize it as the CIMP-positive cluster, the second one being the CIMP-negative cluster (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). The proportion of CIMP-positive samples according to this definition varies from about 20 % for breast and colon cancers to 30 % for bladder and about 60 and 70 % for stomach and lung cancers (Table <xref rid="Tab2" ref-type="table">2</xref>). Proportion of the CIMP-positive group in each tissue is similar to previously reported studies [<xref ref-type="bibr" rid="CR22">22</xref>]. Varying the size of the CIMP signature from 1 to 10 % of all CGIs had a small impact on the clustering stability (Additional file <xref rid="MOESM2" ref-type="media">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>CIMP proportion. For each cancer type, this table shows the number of samples clustered in the CIMP-negative and CIMP-positive clusters and the percentage of CIMP-positive samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Tissue</th><th align="left">Negative</th><th align="left">Positive</th><th align="left">Ratio (%)</th></tr></thead><tbody><tr><td align="left">Bladder</td><td align="left">262</td><td align="left">111</td><td align="left">30</td></tr><tr><td align="left">Breast</td><td align="left">509</td><td align="left">117</td><td align="left">19</td></tr><tr><td align="left">Colon</td><td align="left">232</td><td align="left">59</td><td align="left">20</td></tr><tr><td align="left">Lung</td><td align="left">136</td><td align="left">316</td><td align="left">70</td></tr><tr><td align="left">Stomach</td><td align="left">144</td><td align="left">194</td><td align="left">57</td></tr><tr><td align="left">Overall</td><td align="left">
<italic>1283</italic>
</td><td align="left">
<italic>797</italic>
</td><td align="left">
<italic>38</italic>
</td></tr></tbody></table></table-wrap></p><p>Comparing the epigenetic signatures that define CIMP for each tissue, we find a common set of 89 CGIs associated with 51 genes (Fig. <xref rid="Fig1" ref-type="fig">1</xref><xref rid="Fig1" ref-type="fig">a</xref>). If the signatures were random subsets of 5 % of all CGIs independent from each other, the overlap would contain on average (5 <italic>%</italic>)<sup>5</sup>&#x02243;3.10<sup>&#x02212;5</sup><italic>%</italic> of all CGIs, namely 0.006 CGI. This provides a strong evidence that a common set of genes is involved in CIMP in different cancers. We call these 89 CGIs the <italic>cross-cancer CIMP signature</italic> (Table <xref rid="Tab3" ref-type="table">3</xref>). A hierarchical clustering on all samples restricted to this cross-cancer CIMP signature is able to cluster CIMP-positive and CIMP-negative patients independently of the tissue of origin (Fig. <xref rid="Fig1" ref-type="fig">1</xref><xref rid="Fig1" ref-type="fig">b</xref>), suggesting that CIMP observed in each individual cancer share in common a significant proportion of genes whose promoter CGIs are hypermethylated in all CIMP-positive cancers. A functional enrichment analysis of the cross-cancer CIMP signature reveals that it is significantly enriched in genes involved in cell differentiation and neuronal developmental and immune response processes (Fig. <xref rid="Fig1" ref-type="fig">1</xref><xref rid="Fig1" ref-type="fig">c</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Pan-cancer clustering on common epigenetic signature clusters CIMP-positive and CIMP-negative tumors independently of tissue type. <bold>a</bold> Venn diagram of the CIMP signatures for each tissue. <bold>b</bold> Hierarchical clustering on the common epigenetic signature for all tissues. <bold>c</bold> Gene ontology analysis of the genes associated with the promoters of the common epigenetic signature</p></caption><graphic xlink:href="40246_2015_48_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>List of genes associated with the common set of CGIs that define CIMP in each tissue</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"/><td align="left">LOC339524, GSTM1, CD1D, LMX1A</td></tr><tr><td align="left"/><td align="left">CACNA1E,NR5A2, WNT3A, GNG4</td></tr><tr><td align="left"/><td align="left">EMX1, CTNNA2,LRRTM1, DLX1</td></tr><tr><td align="left"/><td align="left">EVX2, HOXD13, GBX2, SYN2</td></tr><tr><td align="left"/><td align="left">HAND2, NBLA00301, EBF1, HIST1H2BB</td></tr><tr><td align="left">Epigenetic</td><td align="left">HIST1H3C, HLA-DRB1, C6orf186, IKZF1</td></tr><tr><td align="left">Signature</td><td align="left">CDKN2A, HMX3, KNDC1, KLHL35</td></tr><tr><td align="left"/><td align="left">HOTAIR, SLC6A15, ALX1, RFX4</td></tr><tr><td align="left"/><td align="left">CLDN10, ADCY4, RIPK3, NID2</td></tr><tr><td align="left"/><td align="left">OTX2, OTX2OS1, GSC, KIF26A</td></tr><tr><td align="left"/><td align="left">GREM1, SEC14L5, HS3ST3B1, IGF2BP1</td></tr><tr><td align="left"/><td align="left">HOOK2, NFIX, ZNF577, ZNF649</td></tr><tr><td align="left"/><td align="left">CPXM1, CDH22, CHRNA4</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Are there 2 or 3 CIMP classes?</title><p>Several studies suggest the existence of a third class in CIMP phenotype that corresponds to an intermediate level of methylation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. While we enforced an analysis with 2 classes to define the CIMP of each sample as positive or negative in the previous section, we now examine whether the data call for a third class. Following [<xref ref-type="bibr" rid="CR25">25</xref>], we assess the existence of an intermediate CIMP phenotype for each tissue by comparing the increase in empirical cumulative distributive distribution <italic>&#x00394;</italic>(<italic>K</italic>) for different values of <italic>K</italic>=2,&#x02026;,5 where <italic>K</italic> is the number of clusters considered for CIMP.</p><p>Figure <xref rid="Fig2" ref-type="fig">2</xref> shows how <italic>&#x00394;</italic>(<italic>K</italic>) varies as a function of <italic>K</italic> for each cancer, suggesting how many clusters exist in each case. We observe that the existence of a third class is not clear-cut. While colon and breast tissues show a significant increase in <italic>&#x00394;</italic>(<italic>K</italic>) for <italic>K</italic>=3 suggesting a possible third cluster in CIMP, the bladder is flat between 2 and 3 clusters, while lung and gastric cancers do not support the presence of 3 classes. In addition, we assess the stability of 3 clusters by varying the number of CGIs that define CIMP and observed that while CIMP clusters are highly robust for <italic>K</italic>=2, there is some high variability in the cluster definitions for <italic>K</italic>=3 (Additional file <xref rid="MOESM2" ref-type="media">2</xref>). In summary, the presence of 2 clusters is well supported by the data in all cancers, while the third cluster is much more debatable.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Variation in the empirical cumulative distributive function <italic>&#x00394;</italic>(<italic>K</italic>) for each tissue. The empirical cumulative distributive function <italic>&#x00394;</italic>(<italic>K</italic>) is a data-driven criterion which can indicate the number of clusters <italic>K</italic> in the data when it reaches its maximum [<xref ref-type="bibr" rid="CR25">25</xref>]. This plots shows how <italic>&#x00394;</italic>(<italic>K</italic>) varies as a function of <italic>K</italic>, for the different tissues</p></caption><graphic xlink:href="40246_2015_48_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Similar gene expression variations are predictive of CIMP</title><p>To shed light on the relationship between methylation and transcription, we now assess to what extent a transcriptomic signature can classify the samples as CIMP positive or negative. For that purpose, we collected for each family of cancer samples with both methylation and gene expression data available, leading to a subset of samples with an overall proportion of CIMP-positive samples comparable to that of the original dataset (Table <xref rid="Tab4" ref-type="table">4</xref>). We measure by cross-validation how well expression data alone can recover the two CIMP classes.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>CIMP Proportion in samples with both methylation and gene expression data. This table shows the number of CIMP-positive and CIMP-negative samples characterized by both methylation and gene expression data, for each cancer type, as well as the proportion of CIMP-positive samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Tissue</th><th align="left">Negative</th><th align="left">Positive</th><th align="left">Ratio (%)</th></tr></thead><tbody><tr><td align="left">Bladder</td><td align="left">27</td><td align="left">16</td><td align="left">37</td></tr><tr><td align="left">Breast</td><td align="left">385</td><td align="left">93</td><td align="left">20</td></tr><tr><td align="left">Colon</td><td align="left">27</td><td align="left">7</td><td align="left">20</td></tr><tr><td align="left">Lung</td><td align="left">22</td><td align="left">60</td><td align="left">75</td></tr><tr><td align="left">Stomach</td><td align="left">131</td><td align="left">178</td><td align="left">58</td></tr><tr><td align="left">Overall</td><td align="left">
<italic>592</italic>
</td><td align="left">
<italic>354</italic>
</td><td align="left">
<italic>37</italic>
</td></tr></tbody></table></table-wrap></p><p>We first perform a multivariate regression analysis using the lasso technique to assess whether gene expression of a few genes can be predictive of the CIMP status for each tissue separately. The cross-validation accuracies for each family of cancer are shown in Table <xref rid="Tab5" ref-type="table">5</xref>. We observe that while a classifier based on gene expression performs significantly better than random to recover CIMP-positive samples in breast, lung, and stomach cancers, the performance on the bladder and colon is not different from a random classifier. Moreover, we compare the lists of genes selected in the transcriptomic signature after bootstrap resampling of the samples in order to assess their robustness and potential biological significance (Fig. <xref rid="Fig3" ref-type="fig">3</xref><xref rid="Fig3" ref-type="fig">a</xref>). We observe that very few genes are robustly selected in the signatures, and in particular that no gene is associated with BLCA-CIMP and COAD-CIMP prediction in more than 15 % of the bootstrap resampling. In addition, the transcriptomic signatures of different cancers are very diverse, and no gene is present in all of them (Fig. <xref rid="Fig3" ref-type="fig">3</xref><xref rid="Fig3" ref-type="fig">b</xref>). Overall, these results suggest that there is information in the transcriptome related to the CIMP status, but that a robust signature across cancers is difficult to obtain.
<fig id="Fig3"><label>Fig. 3</label><caption><p>Gene expression variations predictive of CIMP. <bold>a</bold> Stability of each gene signature for each tissue-specific CIMP prediction as well as the &#x0201c;Combined-Lasso&#x0201d; and the &#x0201c;Group-Lasso&#x0201d; CIMP prediction task obtained and ranked by frequency of appearance using bootstrap (<italic>n</italic>=100 repeats). For bladder and colon CIMP prediction task, the signature was non-robust (frequency of the most redundant gene inferior to 10 <italic>%</italic>). The combined prediction task signature outperforms the tissue-specific signatures in robustness. <bold>b</bold> Venn diagram of the tissue-specific gene signatures using lasso for each tissue separately. <bold>c</bold> Distribution of the accuracy of the CIMP-phenotype prediction task given the patient gene expression profile using <italic>n</italic>=100 bootstrap and threefold cross-validation for several methods (<italic>pink</italic> = &#x0201c;tissue-specific&#x0201d; lasso, <italic>green</italic> = &#x0201c;Combined-Lasso,&#x0201d; <italic>blue</italic> = &#x0201c;Group-Lasso,&#x0201d; <italic>red star</italic> = random prediction). <bold>d</bold> Venn diagram representing the intersection between the &#x0201c;Combined&#x0201d; and &#x0201c;Group&#x0201d; lasso gene signatures</p></caption><graphic xlink:href="40246_2015_48_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>Accuracy of CIMP prediction using gene expression profiles</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="4">Accuracy</th></tr><tr><th align="left"/><th align="left">Random</th><th align="left">Lasso</th><th align="left">Combined lasso</th><th align="left">Group lasso</th></tr></thead><tbody><tr><td align="left">Bladder</td><td align="left">62.8</td><td align="left">62.9 (<italic>p</italic> = 1)</td><td align="left">74.2 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">72.1 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td></tr><tr><td align="left">Breast</td><td align="left">80.5</td><td align="left">83.9 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">84.7 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">85.5 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td></tr><tr><td align="left">Colon</td><td align="left">79.4</td><td align="left">79.5 (<italic>p</italic> = 1)</td><td align="left">95.0 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">94.2 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td></tr><tr><td align="left">Lung</td><td align="left">73.2</td><td align="left">84.2 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">76.2 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">86.6 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td></tr><tr><td align="left">Stomach</td><td align="left">57.6</td><td align="left">81.2 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">83.0 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td><td align="left">84.8 (<italic>p</italic>&#x02264;2.10<sup>&#x02212;16</sup>)</td></tr><tr><td align="left">Overall</td><td align="left">
<italic>71.9</italic>
</td><td align="left">
<italic>82.4</italic>
</td><td align="left">
<italic>82.6</italic>
</td><td align="left">
<italic>85.0</italic>
</td></tr></tbody></table><table-wrap-foot><p>This table shows the accuracy, assessed by threefold cross-validation repeated 100 times over each tissue (first column), of sample classification in CIMP-positive and CIMP-negative classes from gene expression data using random classification (second column), lasso logistic regression (third column), combined lasso (fourth column), or group lasso logistic regression (fifth column)</p></table-wrap-foot></table-wrap></p><p>However, the poor accuracy as well as the non-robustness of genetic signatures to predict CIMP may be due to the small size of some datasets (<italic>n</italic><sub>BLCA</sub>=43, <italic>n</italic><sub>COAD</sub>=34). To overcome the lack of statistical power due to small sample size, we combine in a second analysis the different datasets into a single multivariate regression analysis, based on the assumption that the CIMP signatures of different cancers may share the same genes. We train classifiers to predict CIMP status from gene expression data jointly across cancers using two methods, based on two different assumptions: (i) assuming that all tissues share the same gene signature and coefficients for the prediction task, we run a single lasso classification on the combined datasets (&#x0201c;Combined-Lasso&#x0201d; prediction) or (ii) assuming that all tissues share the same gene signature but with different coefficients, we jointly train several models with a group lasso approach to constrain the selected genes to be the same across cancers without imposing their coefficients to coincide (&#x0201c;Group-Lasso&#x0201d; prediction) (see supplementary methods in Additional file <xref rid="MOESM3" ref-type="media">3</xref>). The rationale for the group lasso approach is that while CIMP may be caused by a common subset of genes, the specific contribution of each gene may vary between tissues. Our results show that both methods significantly outperform the tissue-specific predictions (<italic>P</italic>&#x02264;2.10<sup>&#x02212;16</sup>, Fig. <xref rid="Fig3" ref-type="fig">3</xref><xref rid="Fig3" ref-type="fig">c</xref>, Table <xref rid="Tab5" ref-type="table">5</xref>) in particular for the bladder and colon where the size of the initial datasets could not give sufficient statistical power to predict CIMP accurately. There is overall little difference between both methods, with the notable exception of lung cancer where the combined lasso approach is significantly worse than the group lasso (and even the single lasso) model, suggesting that in that case, the weights of the genes in the CIMP signature may differ from other cancers. More importantly, each method allows to identify a common genetic signature (51 genes for the &#x0201c;Combined&#x0201d; prediction and 58 genes for the &#x0201c;Group-Lasso&#x0201d; prediction) that distinguishes CIMP-positive and CIMP-negative class for each tumors which is more robust than all the tissue-specific signatures (Fig. <xref rid="Fig3" ref-type="fig">3</xref><xref rid="Fig3" ref-type="fig">d</xref>). In addition, these signatures share a large common set of genes (25 common genes, Table <xref rid="Tab6" ref-type="table">6</xref>). We represented the gene expression distribution for this common set of genes on the different datasets and observe a clear separation between CIMP-positive and CIMP-negative classes for all tissues (Additional file <xref rid="MOESM4" ref-type="media">4</xref>). Gene ontology analysis on the intersection of the two predictive gene signatures showed specific enrichment only for genetic regulatory processes.
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Intersection of the genetic signatures for &#x0201c;Combined-Lasso&#x0201d; and &#x0201c;Group-Lasso&#x0201d; predictive of CIMP ranked by decreasing level of robustness</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"/><td align="left">
<italic>ZIC2</italic>, <italic>AMH</italic>, <italic>LHX1</italic>,</td></tr><tr><td align="left"/><td align="left">
<italic>ZIC3</italic>, <italic>XKR9</italic>,<italic>TNNT1</italic>,</td></tr><tr><td align="left">Over-expressed</td><td align="left">
<italic>CAMK2N2</italic>,<italic>PCDHB9</italic>, <italic>RAET1K</italic>,</td></tr><tr><td align="left"/><td align="left">
<italic>HIST1H2AB</italic>, <italic>C2CD4C</italic>, <italic>FBXL20</italic>,</td></tr><tr><td align="left"/><td align="left">
<italic>TFCP2L1</italic>
</td></tr><tr><td align="left"/><td align="left">
<italic>MAGEC2</italic>, <italic>ZNF300</italic>,<italic>SLC15A1</italic>,<italic>TSPYL5</italic>,</td></tr><tr><td align="left"/><td align="left">
<italic>MLF1</italic>, <italic>GATA2</italic>, <italic>MAGEA12</italic>,</td></tr><tr><td align="left">Under-expressed</td><td align="left">
<italic>LOC441666</italic>, <italic>MAGEA2</italic>, <italic>LOC389493</italic>, <italic>H2AFY2</italic>,</td></tr><tr><td align="left"/><td align="left">
<italic>LDHC</italic>
</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>A genetic signature is associated to CIMP only for colon and gastric cancers</title><p>Several somatic mutations have been found to be tightly associated with epigenetic aberrations in CIMP. Recent studies have pointed out the causal role of IDH1 mutations in Glioblastoma-CIMP [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and tight associations between IDH2 and TET2 mutations with other CIMPs (leukemia [<xref ref-type="bibr" rid="CR26">26</xref>], enchondroma, and spindle cell hemangioma [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]). In the colon, BRAF and KRAS mutations are associated with microsatellite instability and COAD-CIMP [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>We re-assess the association between mutations in these genes and CIMP in the different types of cancers (Fig. <xref rid="Fig4" ref-type="fig">4</xref><xref rid="Fig4" ref-type="fig">a</xref>). We recover a strong association between BRAF mutation and CIMP-positive colon tumors but no specific association with other tumor types. We also find no coordinated association between <italic>IDH1</italic>, <italic>IDH2</italic>, <italic>KRAS</italic>, <italic>BRAF</italic>, or <italic>TET2</italic> mutations and CIMP phenotypes for all tissues. In addition, we perform genome-wide mutation analysis to assess whether specific gene mutations are associated with CIMP. We find no significant gene mutation association for bladder, breast nor lung CIMPs. For colon and gastric cancer, we find respectively 459 and 1070 gene mutations associated with CIMP with a common intersection of 195 genes (Additional file <xref rid="MOESM5" ref-type="media">5</xref> panel A). Gene ontology analysis of this set of genes shows significant enrichment for extracellular matrix organization and cell adhesion but also neuronal developmental processes (Additional file <xref rid="MOESM5" ref-type="media">5</xref> panel B).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Mutation analysis. <bold>a</bold> Association between specific mutations (<italic>IDH1</italic>, <italic>IDH2</italic>, <italic>BRAF</italic>, and <italic>KRAS</italic>) with the CIMP phenotype for all tissues (<italic>yellow</italic> = CIMP positive, <italic>blue</italic> = CIMP negative). <bold>b</bold> Significantly higher mutation rate for CIMP-positive (<italic>yellow</italic>) compared to CIMP-negative (<italic>blue</italic>) tumors is observed for colon and gastric cancers only and is concordant with CIMP association with microsatellite instability for these tissues</p></caption><graphic xlink:href="40246_2015_48_Fig4_HTML" id="MO4"/></fig></p><p>Finally, we also look at the rate of mutations in each tissue given the CIMP phenotype. We observe a significant association between the number of mutations and the CIMP status for colon and gastric cancer (Fig. <xref rid="Fig4" ref-type="fig">4</xref><xref rid="Fig4" ref-type="fig">b</xref>), in accordance with the tight association between CIMP and microsatellite instability for these two tissues [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. However, the same observation could not be made for the bladder, breast, and lung.</p></sec><sec id="Sec7"><title>Clinical impact of CIMP</title><p>Survival analysis in several CIMP studies has often shown distinct outcome between CIMP-positive and CIMP-negative tumors. However, there is no consensus in the general survival associated with CIMP: while CIMP has been associated with improved survival and lower risk of metastasis in breast [<xref ref-type="bibr" rid="CR14">14</xref>], colorectal [<xref ref-type="bibr" rid="CR9">9</xref>], leukemia [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>], or gliomas [<xref ref-type="bibr" rid="CR17">17</xref>], it has also been reportedly associated with poor survival for bladder [<xref ref-type="bibr" rid="CR36">36</xref>], lung [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], or prostate cancers [<xref ref-type="bibr" rid="CR38">38</xref>], and prognosis even remains unclear for gastric cancers [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>We perform a systematic survival analysis on the different tissues to assess the clinical impact of CIMP. However, we observe no significant association between CIMP and survival, in any of the tissues (Table <xref rid="Tab7" ref-type="table">7</xref> and Additional file <xref rid="MOESM6" ref-type="media">6</xref>).
<table-wrap id="Tab7"><label>Table 7</label><caption><p>Clinical impact of CIMP. Overall survival proportion given the CIMP phenotype and the <italic>p</italic> value associated with the survival analysis (logrank test)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Tissue</th><th align="left" colspan="2">Event</th><th align="left">
<italic>p</italic> value</th></tr><tr><th align="left"/><th align="left">CIMP &#x02212;</th><th align="left">CIMP +</th><th align="left"/></tr></thead><tbody><tr><td align="left">BLCA</td><td align="left">47/214</td><td align="left">21/96</td><td align="left">0.74</td></tr><tr><td align="left">BRCA</td><td align="left">29/495</td><td align="left">9/114</td><td align="left">0.20</td></tr><tr><td align="left">COAD</td><td align="left">28/218</td><td align="left">6/54</td><td align="left">0.57</td></tr><tr><td align="left">LUAD</td><td align="left">24/127</td><td align="left">67/295</td><td align="left">0.49</td></tr><tr><td align="left">STAD</td><td align="left">26/141</td><td align="left">20/193</td><td align="left">0.29</td></tr></tbody></table></table-wrap></p><p>Other clinical parameters have been associated with CIMP such as microsatellite instability (MSI) in the colon [<xref ref-type="bibr" rid="CR9">9</xref>] and hormone receptor statuses in the breast [<xref ref-type="bibr" rid="CR14">14</xref>]. We therefore assess the association between the CIMP status and eight clinical annotations provided in the TCGA, namely, age, MSI, ER status, PR status, HER2 status, tumor size, lymph node invasion, and presence of metastasis. We first observe that CIMP is significantly associated with a higher age in the breast, colon, and stomach (<italic>P</italic><sub>breast</sub>=2.10<sup>&#x02212;4</sup>, <italic>P</italic><sub>colon</sub>=2.10<sup>&#x02212;3</sup>, <italic>P</italic><sub>stomach</sub>=0.036, student test, Additional file <xref rid="MOESM7" ref-type="media">7</xref> panel A) but not in the bladder and lung. In the colon, we recover a significant association between CIMP and MSI (<italic>P</italic>=5.10<sup>&#x02212;6</sup>, chi-squared test, Additional file <xref rid="MOESM7" ref-type="media">7</xref> panel B). We also recover a significant association between CIMP and ER, PR, and HER2 statuses in breast (<italic>P</italic><sub>ER</sub>=2.10<sup>&#x02212;5</sup>, <italic>P</italic><sub>PR</sub>=0.03, <italic>P</italic><sub>HER2</sub>=5.10<sup>&#x02212;8</sup>, chi-squared test, Additional file <xref rid="MOESM7" ref-type="media">7</xref> panel C). However, we observed no significant association between CIMP and either tumor size, lymph node invasion, or metastasis in any tissue.</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>CIMP has been thoroughly studied over the past few years in several tissue types but the heterogeneity of the methods and measurement technologies has hindered the assessment of a common epigenetic and genetic signature predictive of CIMP across all cancer sites [<xref ref-type="bibr" rid="CR22">22</xref>]. In the present study, we analyze a large dataset of over 2000 tumor methylation profiles measured with a single technology from 5 different tissue types. We observe a universal epigenetic signature that defines CIMP independently from the tissue of origin, which might suggest a common molecular basis to CIMP across tissues. Genes associated with these CGIs are enriched in several biological pathways linked to organ development and include several interesting genes such as <italic>CDKN2A</italic> coding for p16, a well-characterized tumor suppressor protein [<xref ref-type="bibr" rid="CR44">44</xref>], which is aberrantly hypermethylated in CIMP-positive tumors and might contribute to tumor development. Other genes present in the cross-cancer CIMP signature such as <italic>HOTAIR</italic>, which is known to reprogram the chromatin state and is associated with breast cancer metastasis [<xref ref-type="bibr" rid="CR45">45</xref>], might on the contrary be repressed in CIMP tumors and be linked with a better prognosis for breast cancer patients. <italic>GREM1</italic> is another gene present in the CIMP signature and is associated with tumor cell proliferation [<xref ref-type="bibr" rid="CR46">46</xref>]. Less documented genes present in the CIMP signature could potentially be investigated for a biological validation of their role in tumor development.</p><p>Recent studies have pointed out that epigenetic aberrations could be derived from genetic aberrations [<xref ref-type="bibr" rid="CR47">47</xref>]. By combining the different datasets into a single prediction task, we are able to identify a common set of genes whose expression levels can predict the CIMP status for each tissue. This gene list is enriched mostly in genetic regulatory pathways, suggesting that the epigenetic reprogramming and thus CIMP might be an intermediate step in the regulatory mechanism. Among the genes contained in the signature, <italic>ZIC2</italic>, which is robustly selected in each bootstrap of the CIMP prediction task and is significantly more expressed in CIMP-positive tumors for each tissue, has been known to act as a Wnt/ <italic>&#x003b2;</italic>-catenin signalling inhibitor [<xref ref-type="bibr" rid="CR48">48</xref>] which is usually upregulated in several cancers. Another interesting characteristic of this genetic predictive signature from a clinical point of view is the recurrence of cancer/testis antigens (CTAs) such as <italic>MAGEC2</italic> [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>], <italic>MAGEA12</italic> [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], <italic>MAGEA2</italic> [<xref ref-type="bibr" rid="CR54">54</xref>], and <italic>LDHC</italic> [<xref ref-type="bibr" rid="CR55">55</xref>], which are interesting targets for cancer immunotherapy [<xref ref-type="bibr" rid="CR56">56</xref>] and are consistently under-expressed in CIMP-positive tumors. Recently, Gevaert et al. [<xref ref-type="bibr" rid="CR57">57</xref>] also showed a strong association between <italic>MAGEA4</italic> hypomethylation and CIMP-positive tumors which further supports the link between CTAs and the absence of a methylator phenotype.</p><p>Mutation analyses are not very conclusive in defining a set of specific somatic mutations significantly associated with CIMP. In particular, lowly mutated cancer sites such as the bladder, breast, or even lung do not show any mutations significantly associated with CIMP. For highly mutated cancer sites such as colon or stomach, our results confirm a strong association between <italic>BRAF</italic> mutation and COAD-CIMP [<xref ref-type="bibr" rid="CR9">9</xref>] but do not show any particular associations with <italic>IDH1/2</italic>, which have been reported to be causal in gliomas and leukemia [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. There is a strong association between COAD and STAD-CIMP and the specific mutations of genes related with extracellular matrix and cell adhesion, both reported to be strongly associated with metastasis [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. Interestingly, neuronal developmental processes are highly enriched but affecting different genes from the universal epigenetic signature. Associations with neuronal development were already mentioned in [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Studies have often reported a clear distinct clinical prognosis associated with CIMP [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. This reiterates that a main reason for defining CIMP in each tissue site is its potential use as a prognosis marker. However, CIMP could be associated with a good or bad prognosis depending on the type of tumors. In the current study, we do not observe a significant association with any good nor bad prognosis linked with CIMP.</p></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusion</title><p>This meta-analysis of more than 2000 samples sheds new light on CIMP across cancers, its link with gene expression, and its clinical relevance. We found strong evidence that a panel of genes, which we call the pan-cancer CIMP signature, is involved simultaneously in the establishment of the CIMP in various cancer sites, which might be an indicator of a universal biological process behind CIMP. We found that differences in the CIMP status of a sample is associated to differences in the transcriptome, and also found a core set of genes whose expression levels differentiates CIMP-positive and CIMP-negative samples, in all cancers studied. Finally, we found little evidence of association between CIMP and mutations, except for the well-known BRAF mutation in colon cancer and also little association with patient survival.</p></sec><sec id="Sec10" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec11"><title>Patient selection</title><p>All data were retrieved from the TCGA data portal. We selected samples from bladder, breast, colon, lung and gastric adenocarcinomas because large matched datasets were available for methylation, gene expression, and mutation profiles. Moreover, all these tissues were previously reported to exhibit a methylator phenotype. The datasets are detailed in Table <xref rid="Tab1" ref-type="table">1</xref> and the different institutions that released the data are mentioned in the &#x0201c;Acknowledgements&#x0201d; section.</p></sec><sec id="Sec12"><title>Methylation profiling</title><p>Methylation profiles were retrieved from level 2 TCGA data. They were obtained with the Illumina HumanMethylation450K DNA Analysis BeadChip assay, which is based on genotyping of bisulfite-converted genomic DNA at individual CpG sites to provide a quantitative measure of DNA methylation [<xref ref-type="bibr" rid="CR62">62</xref>]. Following hybridization, the methylation value for a specific probe was calculated as the ratio <italic>M</italic>/(<italic>M</italic>+<italic>U</italic>) where <italic>M</italic> is the methylated signal intensity and <italic>U</italic> is the unmethylated signal intensity. Across the genome, 485,577 CpG methylation levels, associated with 27,176 CGIs and 21,231 genes, were measured as such.</p><p>Following [<xref ref-type="bibr" rid="CR63">63</xref>], we considered not only the CGI methylation profile but also included in the analysis proximal regions in the near vicinity (up to 4 kb), namely the CGI Shores and Shelves regions in a general CGI + SS methylation profile.</p></sec><sec id="Sec13"><title>Gene expression profiling</title><p>Gene expression profiles were retrieved from level 3 TCGA data. They were obtained from the Illumina HiSeq RNASeq technology and processed following [<xref ref-type="bibr" rid="CR64">64</xref>]. We used the reads per kilobase per million mapped reads (RPKM) to quantify the gene expression level from RNA sequencing data.</p></sec><sec id="Sec14"><title>Mutation profiling</title><p>Mutation profiles were retrieved from somatic mutation profiles from level 2 TCGA data obtained through whole exome sequencing. To compare the rate of mutation given the CIMP status, we performed a hypergeometric test and corrected for multiple testing using Benjamini-Hochberg correction.</p></sec><sec id="Sec15"><title>CIMP analysis</title><p>To assess the existence of CIMP, we performed Ward hierarchical clustering using euclidean distance on the top 5 % most variant CGIs. Variations from 1 to 10 % of the most variant CGIs had a small impact on the clustering stability (Additional file <xref rid="MOESM3" ref-type="media">3</xref>). We then cut the hierarchical clustering tree in two classes namely CIMP-positive and CIMP-negative tumors given their average level of methylation (CIMP-positive = high level of methylation, CIMP-negative = low level of methylation). Robustness of the clustering was obtained through consensus clustering [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec16"><title>Predicting CIMP status from gene expression profiles</title><p>We performed logistic regression using a lasso penalty [<xref ref-type="bibr" rid="CR65">65</xref>] to predict CIMP status from gene expression profiles for each tissue separately. Accuracy is calculated through threefold cross-validation averaged over 100 repeats. To combine the different datasets into a single prediction task, we performed group-lasso logistic regression (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Given the imbalanced proportion of CIMP in each datasets, we defined the &#x0201c;random&#x0201d; predictor as a predictor that always predicts the majority class. The statistical significance of a gene expression-based predictor over the &#x0201c;random&#x0201d; predictor was calculated using a Student <italic>t</italic> test.</p><p>To determine the genetic predictive signature, genes were ranked according to the frequency at which they appeared in the optimal lasso estimator signature averaged over the different folds and repeats. Genes with a frequency of at least 50 % were selected.</p></sec><sec id="Sec17"><title>Survival analysis</title><p>Overall survival was estimated using the Kaplan-Meier method [<xref ref-type="bibr" rid="CR66">66</xref>] to compare the survival between CIMP-positive and CIMP-negative tumors. A multivariate Cox proportional hazards regression model [<xref ref-type="bibr" rid="CR67">67</xref>] was also fitted to assess the CIMP odd ratio.</p></sec></sec><sec id="Sec18"><title>Endnotes</title><p><sup>1</sup>Bladder tissue <sup>2</sup>Breast tissue <sup>3</sup>Colon tissue <sup>4</sup>Lung tissue <sup>5</sup>Stomach tissue</p></sec></body><back><app-group><app id="App1"><sec id="Sec19"><title>Additional files</title><p><media position="anchor" xlink:href="40246_2015_48_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1</label><caption><p>
<bold>Hierarchical clustering and CIMP status of samples in each tissue.</bold> Each sample is represented by the methylation levels of the 5 % of the probes that vary most in the tissue considered. Heatmaps range from hypomethylated (<italic>blue</italic>) to hypermethylated (<italic>yellow</italic>). The <italic>column colorbar</italic> represents the resulting assignment of each sample as CIMP positive (<italic>yellow</italic>) or CIMP negative (<italic>blue</italic>). Panel A. bladder; panel B. breast; panel C. colon; panel D. lung; panel E. stomach. (PDF 13722 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2</label><caption><p>
<bold>Stability of CIMP clusters with respect to the size of the CIMP signature.</bold> Robustness of cluster assignment for each sample (<italic>columns</italic>) as a function of the proportion of variant CGIs kept to define the CIMP signature, from 1 to 10 % (<italic>rows</italic>) and given the number of CIMP clusters considered (<italic>left panels</italic>: K = 2, <italic>right panels</italic>: K = 3, <italic>yellow</italic> = CIMP-positive, <italic>blue</italic> = CIMP-negative, <italic>black</italic> = CIMP-low) for bladder (panel A/B), breast (panel C/D), colon (panel E/F), lung (panel G/H), stomach (panel I/J). Panel K. Table summarizing the stability of the cluster assignments for each tissue and different number of CIMP clusters considered. (PDF 381 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM3_ESM.pdf" id="MOESM3"><label>Additional file 3</label><caption><p>
<bold>Supplementary methods.</bold> (PDF 153 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM4_ESM.pdf" id="MOESM4"><label>Additional file 4</label><caption><p>
<bold>Gene expression profiling on the common genetic predictive signature for each tissue.</bold> The <italic>column color bar</italic> represents the CIMP status (<italic>yellow</italic> = CIMP-positive, <italic>blue</italic> = CIMP-negative) while the <italic>row color bar</italic> represents the clustering of genes (<italic>green</italic> = under-expressed in CIMP, red = over-expressed in CIMP). Panel A. bladder; panel B. breast; panel C. colon; panel D. lung; panel E. stomach. (PDF 561 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM5_ESM.pdf" id="MOESM5"><label>Additional file 5</label><caption><p>
<bold>Study of a genetic signature associated with CIMP.</bold> Panel A. Venn diagram representing the intersection of the mutations significantly associated with CIMP in colon and gastric cancers. Panel B. Gene ontology analysis of the common genes associated with CIMP. (PDF 82 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM6_ESM.pdf" id="MOESM6"><label>Additional file 6</label><caption><p>
<bold>Clinical impact of CIMP on the patient surival.</bold> The plots show the Kaplan Meier survival curves based on CIMP status for different tissues. Panel A. bladder; panel B. breast; panel C. colon; panel D. lung; panel E. stomach. (PDF 89 kb)</p></caption></media></p><p><media position="anchor" xlink:href="40246_2015_48_MOESM7_ESM.pdf" id="MOESM7"><label>Additional file 7</label><caption><p>
<bold>Association between CIMP and clinical annotations.</bold> Panel A. Association between CIMP and age: distribution of patients&#x02019; age given their CIMP phenotype in each tissue. Panel B. Association between CIMP and MSI in colon: ratio of MSI-positive and MSI-negative patient given the CIMP phenotype in the colon. Panel C. Association between CIMP and ER status in breast: ratio of ER-positive patients given the CIMP phenotype in the breast. Panel D. Association between CIMP and PR status in the breast: ratio of PR-positive patients given the CIMP phenotype in the breast. Panel E. Association between CIMP and HER2 status in the breast: ratio of HER2-positive patients given the CIMP phenotype in the breast. (PDF 86 kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CIMP</term><def><p>CpG island methylator phenotype</p></def></def-item><def-item><term>CGI</term><def><p>CpG island</p></def></def-item><def-item><term>BLCA</term><def><p>Bladder carcinoma</p></def></def-item><def-item><term>BRCA</term><def><p>Breast carcinoma</p></def></def-item><def-item><term>COAD</term><def><p>Colon adenocarcinoma</p></def></def-item><def-item><term>LUAD</term><def><p>Lung adenocarcinoma</p></def></def-item><def-item><term>STAD</term><def><p>Stomach adenocarcinoma</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MM participated in the statistical analyses and the writing of the manuscript. FR and JPV conceived the study and participated in its design and coordination. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was financially supported by &#x0201c;La Ligue Nationale Contre le Cancer&#x0201d; (to MM) and the European Research Council (SMAC-ERC-280032 to JPV and MM).</p><p>The authors would like to acknowledge the following: the Cancer Genome Atlas, IUPUI <sup>1,2,4,5</sup>, Lahey Clinic <sup>1,4</sup>, Research Metrics Pakistan <sup>2</sup>, Asterand <sup>1,2,3,4,5</sup>, Baylor <sup>1,3,4</sup>, Cleveland Clinic <sup>1</sup>, UT Southwestern Medical Center at Dallas <sup>1</sup>, University of Chicago <sup>1</sup>, University of Miami <sup>1</sup>, Barretos Cancer Hospital <sup>1,5</sup>, Penrose Colorado <sup>1,4</sup>, Candler <sup>1,3,4,5</sup>, Christiana Healthcare <sup>1,2,3,4,5</sup>, Cornell Medical College <sup>1</sup>, Cureline <sup>2,3,4,5</sup>, Duke <sup>2</sup>, Erasmus MC <sup>1</sup>, Fox Chase <sup>4,5</sup>, Global Bioclinical-Moldova <sup>5</sup>, Greater Poland Cancer Center <sup>2,3,5</sup>, Gundersen Lutheran Health System <sup>1,4</sup>, Hartford Hospital <sup>1</sup>, Harvard <sup>3</sup>, ILSBio <sup>1,2,3,4,5</sup>, Indivumed <sup>1,2,3,4,5</sup>, International Genomics Consortium <sup>1,2,3,4,5</sup>, Johns Hopkins <sup>4</sup>, MD Anderson Cancer Center <sup>1,2,5</sup>, Memorial Sloan Kettering Cancer Center <sup>2,3,5</sup>, Mayo Clinic <sup>1,2</sup>, Medical College of Georgia <sup>1</sup>, National Cancer Center Korea <sup>5</sup>, Ontario Institute for Cancer Research <sup>1,2,3,4,5</sup>, Peter MacCallum Cancer Center <sup>5</sup>, Prince Charles Hospital <sup>4</sup>, Roswell Park <sup>1,2,3,4</sup>, Spectrum Health <sup>1</sup>, St Joseph Medical Center <sup>3,4</sup>, Tayside Tissue Bank <sup>5</sup>, Thoraxklinik at University Hospital Heidelberg <sup>4</sup>, UCSF <sup>2</sup>, UNC <sup>1,2,3,4,5</sup>, University Health Network <sup>5</sup>, University of Michigan <sup>3</sup>, University of Colorado Denver <sup>1</sup>, University of Miami <sup>2,4</sup>, University of Minnesota <sup>1</sup>, University of Oklahoma <sup>1</sup>, University of Pittsburgh <sup>1,2,3,4,5</sup>, University of Puerto Rico <sup>1</sup>, University of Sheffield <sup>1</sup>, University of Southern California <sup>1</sup>, Walter Reed <sup>2</sup>, Washington University <sup>4</sup> for the distribution of patients data (as specified below);</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>The epigenomics of cancer</article-title><source>Cell</source><year>2007</year><volume>128</volume><issue>4</issue><fpage>683</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.01.029</pub-id><?supplied-pmid 17320506?><pub-id pub-id-type="pmid">17320506</pub-id></element-citation></ref><ref id="CR2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Epigenetics in cancer</article-title><source>New Eng J Med</source><year>2008</year><volume>358</volume><issue>11</issue><fpage>1148</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1056/NEJMra072067</pub-id><?supplied-pmid 18337604?><pub-id pub-id-type="pmid">18337604</pub-id></element-citation></ref><ref id="CR3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Paredes</surname><given-names>M</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Cancer epigenetics reaches mainstream oncology</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><issue>3</issue><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nm.2305</pub-id><?supplied-pmid 21386836?><pub-id pub-id-type="pmid">21386836</pub-id></element-citation></ref><ref id="CR4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P</given-names></name></person-group><article-title>DNA methylation and cancer</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><issue>2</issue><fpage>461</fpage><lpage>6</lpage><?supplied-pmid 2416425?><pub-id pub-id-type="pmid">2416425</pub-id></element-citation></ref><ref id="CR5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>DNA hypermethylation in tumorigenesis: epigenetics joins genetics</article-title><source>Trends Genet</source><year>2000</year><volume>16</volume><issue>4</issue><fpage>168</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0168-9525(99)01971-X</pub-id><?supplied-pmid 10729832?><pub-id pub-id-type="pmid">10729832</pub-id></element-citation></ref><ref id="CR6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Corn</surname><given-names>PG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>A gene hypermethylation profile of human cancer</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><issue>8</issue><fpage>3225</fpage><lpage>9</lpage><?supplied-pmid 11309270?><pub-id pub-id-type="pmid">11309270</pub-id></element-citation></ref><ref id="CR7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Ahuja</surname><given-names>N</given-names></name><name><surname>Ohe-Toyota</surname><given-names>M</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Issa</surname><given-names>J-PJ</given-names></name></person-group><article-title>CpG island methylator phenotype in colorectal cancer</article-title><source>Proc Nat Acad Sci</source><year>1999</year><volume>96</volume><issue>July</issue><fpage>8681</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.15.8681</pub-id><?supplied-pmid 10411935?><pub-id pub-id-type="pmid">10411935</pub-id></element-citation></ref><ref id="CR8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Issa</surname><given-names>J-PJ</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name></person-group><article-title>CIMP, at last</article-title><source>Gastroenterology</source><year>2005</year><volume>129</volume><issue>3</issue><fpage>1121</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.07.040</pub-id><?supplied-pmid 16143149?><pub-id pub-id-type="pmid">16143149</pub-id></element-citation></ref><ref id="CR9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Siegmund</surname><given-names>KD</given-names></name><name><surname>Campan</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>TI</given-names></name><name><surname>Faasse</surname><given-names>Ma</given-names></name><etal/></person-group><article-title>CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><issue>7</issue><fpage>787</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/ng1834</pub-id><?supplied-pmid 16804544?><pub-id pub-id-type="pmid">16804544</pub-id></element-citation></ref><ref id="CR10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Est&#x000e9;cio</surname><given-names>MRH</given-names></name><name><surname>Yan</surname><given-names>PS</given-names></name><name><surname>Ibrahim</surname><given-names>AEK</given-names></name><name><surname>Tellez</surname><given-names>CS</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>TH-M</given-names></name><etal/></person-group><article-title>High-throughput methylation profiling by MCA coupled to CpG island microarray</article-title><source>Genome Res</source><year>2007</year><volume>17</volume><issue>10</issue><fpage>1529</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1101/gr.6417007</pub-id><?supplied-pmid 17785535?><pub-id pub-id-type="pmid">17785535</pub-id></element-citation></ref><ref id="CR11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>K</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Samowitz</surname><given-names>WS</given-names></name></person-group><article-title>CpG island methylation in colorectal cancer: past, present and future</article-title><source>Pathol Res Int</source><year>2011</year><volume>2011</volume><fpage>902674</fpage><pub-id pub-id-type="doi">10.4061/2011/902674</pub-id></element-citation></ref><ref id="CR12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinoue</surname><given-names>T</given-names></name><name><surname>Weinsenberger</surname><given-names>D</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Byun</surname><given-names>H</given-names></name><name><surname>Van Den Berg</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genome-scale analysis of aberrant DNA methylation in colorectal cancer</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>271</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1101/gr.117523.110</pub-id><?supplied-pmid 21659424?><pub-id pub-id-type="pmid">21659424</pub-id></element-citation></ref><ref id="CR13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Auwera</surname><given-names>I</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Suo</surname><given-names>L</given-names></name><name><surname>Van Neste</surname><given-names>L</given-names></name><name><surname>van Dam</surname><given-names>P</given-names></name><name><surname>Van Marck</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Array-based DNA methylation profiling for breast cancer subtype discrimination</article-title><source>PloS One</source><year>2010</year><volume>5</volume><issue>9</issue><fpage>e12616</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0012616</pub-id><?supplied-pmid 20830311?><pub-id pub-id-type="pmid">20830311</pub-id></element-citation></ref><ref id="CR14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Rimner</surname><given-names>A</given-names></name><name><surname>Kaufman</surname><given-names>A</given-names></name><name><surname>Giri</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>LGT</given-names></name><etal/></person-group><article-title>Breast cancer methylomes establish an epigenomic foundation for metastasis</article-title><source>Sci Trans Med</source><year>2011</year><volume>3</volume><issue>75</issue><fpage>75</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3001875</pub-id></element-citation></ref><ref id="CR15"><label>15</label><mixed-citation publication-type="other">Suzuki M, Shigematsu H, Lizasa T, Hiroshima K, Nakatani Y, Minna J, et al, Cancer. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. 2006; 106(10):2200&#x02013;7.</mixed-citation></ref><ref id="CR16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Zhu</surname><given-names>BH</given-names></name><name><surname>Zhang</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>DJ</given-names></name><name><surname>Peng</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><etal/></person-group><article-title>High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer</article-title><source>Cancer Sci</source><year>2012</year><volume>103</volume><issue>1</issue><fpage>73</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.02129.x</pub-id><?supplied-pmid 22017425?><pub-id pub-id-type="pmid">22017425</pub-id></element-citation></ref><ref id="CR17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Diefes</surname><given-names>K</given-names></name><name><surname>Phillips</surname><given-names>HS</given-names></name><name><surname>Pujara</surname><given-names>K</given-names></name><name><surname>Berman</surname><given-names>BP</given-names></name><etal/></person-group><article-title>Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma</article-title><source>Cancer Cell</source><year>2010</year><volume>17</volume><issue>5</issue><fpage>510</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.03.017</pub-id><?supplied-pmid 20399149?><pub-id pub-id-type="pmid">20399149</pub-id></element-citation></ref><ref id="CR18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baysan</surname><given-names>M</given-names></name><name><surname>Bozdag</surname><given-names>S</given-names></name><name><surname>Cam</surname><given-names>MC</given-names></name><name><surname>Kotliarova</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Walling</surname><given-names>J</given-names></name><etal/></person-group><article-title>G-CIMP status prediction of glioblastoma samples using mRNA expression data</article-title><source>PloS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>47839</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0047839</pub-id></element-citation></ref><ref id="CR19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Campos</surname><given-names>C</given-names></name><name><surname>Fabius</surname><given-names>AWM</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><etal/></person-group><article-title>IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype</article-title><source>Nature</source><year>2012</year><volume>483</volume><issue>7390</issue><fpage>479</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nature10866</pub-id><?supplied-pmid 22343889?><pub-id pub-id-type="pmid">22343889</pub-id></element-citation></ref><ref id="CR20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>YK</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Garrett</surname><given-names>E</given-names></name><name><surname>Bornman</surname><given-names>D</given-names></name><name><surname>Fackler</surname><given-names>MJ</given-names></name><name><surname>Sukumar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hypermethylation in histologically distinct classes of breast cancer</article-title><source>Clinical Cancer Res</source><year>2004</year><volume>10</volume><issue>18</issue><fpage>5998</fpage><lpage>6005</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0667</pub-id><pub-id pub-id-type="pmid">15447983</pub-id></element-citation></ref><ref id="CR21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anacleto</surname><given-names>C</given-names></name><name><surname>Leopoldino</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>B</given-names></name><name><surname>Soares</surname><given-names>FA</given-names></name><name><surname>Lopes</surname><given-names>A</given-names></name><name><surname>Rocha</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Colorectal cancer &#x0201c;methylator phenotype&#x0201d;: fact or artifact?</article-title><source>Neoplasia</source><year>2005</year><volume>7</volume><issue>4</issue><fpage>331</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1593/neo.04502</pub-id><?supplied-pmid 15967110?><pub-id pub-id-type="pmid">15967110</pub-id></element-citation></ref><ref id="CR22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>LAE</given-names></name><name><surname>Melotte</surname><given-names>V</given-names></name><name><surname>de Schrijver</surname><given-names>J</given-names></name><name><surname>de Maat</surname><given-names>M</given-names></name><name><surname>Smit</surname><given-names>VTHBM</given-names></name><name><surname>Bovee</surname><given-names>JVMG</given-names></name><etal/></person-group><article-title>The CpG island methylator phenotype: what&#x02019;s in a name?</article-title><source>Cancer research</source><year>2013</year><volume>73</volume><issue>19</issue><fpage>5858</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-4306</pub-id><?supplied-pmid 23801749?><pub-id pub-id-type="pmid">23801749</pub-id></element-citation></ref><ref id="CR23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Kirkner</surname><given-names>GJ</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name></person-group><article-title>CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations</article-title><source>J Mol Diagn</source><year>2006</year><volume>8</volume><issue>5</issue><fpage>582</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2353/jmoldx.2006.060082</pub-id><?supplied-pmid 17065427?><pub-id pub-id-type="pmid">17065427</pub-id></element-citation></ref><ref id="CR24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>47</issue><fpage>18654</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.0704652104</pub-id><?supplied-pmid 18003927?><pub-id pub-id-type="pmid">18003927</pub-id></element-citation></ref><ref id="CR25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>J</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name></person-group><article-title>Consensus Clustering : A Resampling-Based Method for Class Discovery and Visualization of Gene</article-title><source>Machine Learning</source><year>2003</year><volume>52</volume><issue>1</issue><fpage>91</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1023/A:1023949509487</pub-id></element-citation></ref><ref id="CR26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>M</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Shih</surname><given-names>A</given-names></name><etal/></person-group><article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title><source>Cancer Cell</source><year>2010</year><volume>18</volume><issue>6</issue><fpage>553</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.015</pub-id><?supplied-pmid 21130701?><pub-id pub-id-type="pmid">21130701</pub-id></element-citation></ref><ref id="CR27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amary</surname><given-names>M</given-names></name><name><surname>Damato</surname><given-names>S</given-names></name><name><surname>Halai</surname><given-names>D</given-names></name><name><surname>Eskandarpour</surname><given-names>M</given-names></name><name><surname>Berisha</surname><given-names>F</given-names></name><name><surname>Bonar</surname><given-names>F</given-names></name></person-group><article-title>Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><issue>12</issue><fpage>1262</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/ng.994</pub-id><?supplied-pmid 22057236?><pub-id pub-id-type="pmid">22057236</pub-id></element-citation></ref><ref id="CR28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pansuriya</surname><given-names>T</given-names></name><name><surname>van Eijk</surname><given-names>R</given-names></name><name><surname>d&#x02019;Adamo</surname><given-names>P</given-names></name><name><surname>van Ruler</surname><given-names>M</given-names></name><name><surname>Kuijjer</surname><given-names>M</given-names></name><name><surname>Oosting</surname><given-names>J</given-names></name><etal/></person-group><article-title>Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><issue>12</issue><fpage>1256</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/ng.1004</pub-id><?supplied-pmid 22057234?><pub-id pub-id-type="pmid">22057234</pub-id></element-citation></ref><ref id="CR29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>J</given-names></name><name><surname>Umar</surname><given-names>A</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Graff</surname><given-names>J</given-names></name><name><surname>Ahuja</surname><given-names>N</given-names></name><name><surname>Issa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><issue>12</issue><fpage>6870</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.12.6870</pub-id><?supplied-pmid 9618505?><pub-id pub-id-type="pmid">9618505</pub-id></element-citation></ref><ref id="CR30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Parsons</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Kristel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types</article-title><source>Hum Mutat</source><year>2012</year><volume>33</volume><issue>1</issue><fpage>100</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1002/humu.21633</pub-id><?supplied-pmid 22009941?><pub-id pub-id-type="pmid">22009941</pub-id></element-citation></ref><ref id="CR31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>Z</given-names></name><name><surname>Cutcutache</surname><given-names>I</given-names></name><name><surname>Poon</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>McPherson</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><issue>5</issue><fpage>570</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/ng.2246</pub-id><?supplied-pmid 22484628?><pub-id pub-id-type="pmid">22484628</pub-id></element-citation></ref><ref id="CR32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Kopecky</surname><given-names>K</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Jair</surname><given-names>K</given-names></name><name><surname>Willman</surname><given-names>C</given-names></name><name><surname>Issa</surname><given-names>J</given-names></name></person-group><article-title>Methylation profiling in acute myeloid leukemia</article-title><source>Blood</source><year>2001</year><volume>97</volume><issue>9</issue><fpage>2823</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.9.2823</pub-id><?supplied-pmid 11313277?><pub-id pub-id-type="pmid">11313277</pub-id></element-citation></ref><ref id="CR33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Daniel</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Kornblau</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal/></person-group><article-title>DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia</article-title><source>Clinical Cancer Res</source><year>2002</year><volume>8</volume><issue>7</issue><fpage>2217</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12114423</pub-id></element-citation></ref><ref id="CR34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman-Gomez</surname><given-names>J</given-names></name><name><surname>Jimenez-Velasco</surname><given-names>A</given-names></name><name><surname>Agirre</surname><given-names>X</given-names></name><name><surname>Prosper</surname><given-names>F</given-names></name><name><surname>Heiniger</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>28</issue><fpage>7043</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.01.4944</pub-id><?supplied-pmid 16192589?><pub-id pub-id-type="pmid">16192589</pub-id></element-citation></ref><ref id="CR35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman-Gomez</surname><given-names>J</given-names></name><name><surname>Jimenez-Velasco</surname><given-names>A</given-names></name><name><surname>Agirre</surname><given-names>X</given-names></name><name><surname>Castillejo</surname><given-names>J</given-names></name><name><surname>Navarro</surname><given-names>G</given-names></name><name><surname>Calasanz</surname><given-names>M</given-names></name><etal/></person-group><article-title>CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia</article-title><source>Clinical Cancer Res</source><year>2006</year><volume>12</volume><issue>16</issue><fpage>4845</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2592</pub-id><pub-id pub-id-type="pmid">16914570</pub-id></element-citation></ref><ref id="CR36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>R</given-names></name><name><surname>Toyooka</surname><given-names>S</given-names></name><name><surname>Toyooka</surname><given-names>K</given-names></name><name><surname>Harada</surname><given-names>K</given-names></name><name><surname>Virmani</surname><given-names>A</given-names></name><name><surname>Zochbauer-Muller</surname><given-names>S</given-names></name><etal/></person-group><article-title>Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><issue>24</issue><fpage>8659</fpage><lpage>63</lpage><?supplied-pmid 11751381?><pub-id pub-id-type="pmid">11751381</pub-id></element-citation></ref><ref id="CR37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><etal/></person-group><article-title>CpG island methylator phenotype involving tumor suppressor genes located o chromosome 3p in non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2008</year><volume>62</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2008.02.005</pub-id><?supplied-pmid 18358560?><pub-id pub-id-type="pmid">18358560</pub-id></element-citation></ref><ref id="CR38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>R</given-names></name><name><surname>Toyooka</surname><given-names>S</given-names></name><name><surname>Toyooka</surname><given-names>K</given-names></name><name><surname>Virmani</surname><given-names>A</given-names></name><name><surname>Zochbauer-Muller</surname><given-names>S</given-names></name><name><surname>Farinas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features</article-title><source>Clinical Cancer Res</source><year>2002</year><volume>8</volume><issue>2</issue><fpage>514</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11839671</pub-id></element-citation></ref><ref id="CR39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Ahuja</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Ohe-Toyota</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>5438</fpage><lpage>42</lpage><?supplied-pmid 10554013?><pub-id pub-id-type="pmid">10554013</pub-id></element-citation></ref><ref id="CR40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oue</surname><given-names>N</given-names></name><name><surname>Oshimo</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>R</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Matsusaki</surname><given-names>K</given-names></name><etal/></person-group><article-title>DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype</article-title><source>Cancer Sci</source><year>2003</year><volume>94</volume><issue>10</issue><fpage>901</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01373.x</pub-id><?supplied-pmid 14556664?><pub-id pub-id-type="pmid">14556664</pub-id></element-citation></ref><ref id="CR41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Noh</surname><given-names>S</given-names></name></person-group><article-title>Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability</article-title><source>J Pathol</source><year>2003</year><volume>200</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/path.1325</pub-id><?supplied-pmid 12692837?><pub-id pub-id-type="pmid">12692837</pub-id></element-citation></ref><ref id="CR42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etoh</surname><given-names>T</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Ushijima</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers</article-title><source>Am J Pathol</source><year>2004</year><volume>164</volume><issue>2</issue><fpage>689</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63156-2</pub-id><?supplied-pmid 14742272?><pub-id pub-id-type="pmid">14742272</pub-id></element-citation></ref><ref id="CR43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusano</surname><given-names>M</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Akino</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>F</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus</article-title><source>Cancer</source><year>2006</year><volume>106</volume><issue>7</issue><fpage>1467</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/cncr.21789</pub-id><?supplied-pmid 16518809?><pub-id pub-id-type="pmid">16518809</pub-id></element-citation></ref><ref id="CR44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobori</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>DJ</given-names></name><name><surname>Lois</surname><given-names>A</given-names></name><name><surname>Takabayashi</surname><given-names>K</given-names></name><name><surname>Carson</surname><given-names>DA</given-names></name></person-group><article-title>Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers</article-title><source>Nature</source><year>1994</year><volume>368</volume><issue>April</issue><fpage>753</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/368753a0</pub-id><?supplied-pmid 8152487?><pub-id pub-id-type="pmid">8152487</pub-id></element-citation></ref><ref id="CR45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RA</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Wong</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis</article-title><source>Nature</source><year>2010</year><volume>464</volume><issue>7291</issue><fpage>1071</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature08975</pub-id><?supplied-pmid 20393566?><pub-id pub-id-type="pmid">20393566</pub-id></element-citation></ref><ref id="CR46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sneddon</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>H</given-names></name><name><surname>Montgomery</surname><given-names>K</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Tward</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><issue>40</issue><fpage>14842</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.0606857103</pub-id><?supplied-pmid 17003113?><pub-id pub-id-type="pmid">17003113</pub-id></element-citation></ref><ref id="CR47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddington</surname><given-names>JP</given-names></name><name><surname>Sproul</surname><given-names>D</given-names></name><name><surname>Meehan</surname><given-names>RR</given-names></name></person-group><article-title>DNA methylation reprogramming in cancer: does it act by re-configuring the binding landscape of Polycomb repressive complexes?</article-title><source>BioEssays: News Rev Mol Cell Dev Biol</source><year>2014</year><volume>36</volume><issue>2</issue><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/bies.201300130</pub-id></element-citation></ref><ref id="CR48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourebrahim</surname><given-names>R</given-names></name><name><surname>Houtmeyers</surname><given-names>R</given-names></name><name><surname>Ghogomu</surname><given-names>S</given-names></name><name><surname>Janssens</surname><given-names>S</given-names></name><name><surname>Thelie</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><etal/></person-group><article-title>Transcription factor Zic2 inhibits Wnt/beta-catenin protein signaling</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>43</issue><fpage>37732</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.242826</pub-id><?supplied-pmid 21908606?><pub-id pub-id-type="pmid">21908606</pub-id></element-citation></ref><ref id="CR49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>von Boehmer L</collab><name><surname>Keller</surname><given-names>L</given-names></name><name><surname>Mortezavi</surname><given-names>A</given-names></name><name><surname>Provenzano</surname><given-names>M</given-names></name><name><surname>Sais</surname><given-names>G</given-names></name><name><surname>Hermanns</surname><given-names>T</given-names></name><etal/></person-group><article-title>MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>7</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0021366</pub-id></element-citation></ref><ref id="CR50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Hang</surname><given-names>X</given-names></name><name><surname>Tie</surname><given-names>R</given-names></name><etal/></person-group><article-title>MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis</article-title><source>Breast Cancer Res Treatment</source><year>2014</year><volume>145</volume><issue>1</issue><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s10549-014-2915-9</pub-id></element-citation></ref><ref id="CR51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>H</given-names></name><name><surname>Yousef</surname><given-names>S</given-names></name><name><surname>Luetkens</surname><given-names>T</given-names></name><name><surname>Fehse</surname><given-names>B</given-names></name><name><surname>Berdien</surname><given-names>B</given-names></name><name><surname>Kr&#x000f6;ger</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients</article-title><source>Blood Cancer J</source><year>2014</year><volume>4</volume><fpage>e212</fpage><pub-id pub-id-type="doi">10.1038/bcj.2014.31</pub-id><?supplied-pmid 24813080?><pub-id pub-id-type="pmid">24813080</pub-id></element-citation></ref><ref id="CR52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidecker</surname><given-names>L</given-names></name><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Probst-Kepper</surname><given-names>M</given-names></name><name><surname>Gu&#x000e9;guen</surname><given-names>M</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Van den Eynde</surname><given-names>BJ</given-names></name></person-group><article-title>Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12</article-title><source>J Immunol (Baltimore, Md. : 1950)</source><year>2000</year><volume>164</volume><issue>11</issue><fpage>6041</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.11.6041</pub-id></element-citation></ref><ref id="CR53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollaoglu</surname><given-names>N</given-names></name><name><surname>Vairaktaris</surname><given-names>E</given-names></name><name><surname>Nkenke</surname><given-names>E</given-names></name><name><surname>Neukam</surname><given-names>FW</given-names></name><name><surname>Ries</surname><given-names>J</given-names></name></person-group><article-title>Expression of MAGE-A12 in oral squamous cell carcinoma</article-title><source>Disease Markers</source><year>2008</year><volume>24</volume><issue>1</issue><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1155/2008/359840</pub-id><?supplied-pmid 18057533?><pub-id pub-id-type="pmid">18057533</pub-id></element-citation></ref><ref id="CR54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peche</surname><given-names>LY</given-names></name><name><surname>Scolz</surname><given-names>M</given-names></name><name><surname>Ladelfa</surname><given-names>MF</given-names></name><name><surname>Monte</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name></person-group><article-title>MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs</article-title><source>Cell Death Differentiation</source><year>2012</year><volume>19</volume><issue>6</issue><fpage>926</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.173</pub-id><?supplied-pmid 22117195?><pub-id pub-id-type="pmid">22117195</pub-id></element-citation></ref><ref id="CR55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Goldberg</surname><given-names>E</given-names></name></person-group><article-title>Homo sapiens lactate dehydrogenase c (Ldhc) gene expression in cancer cells is regulated by transcription factor Sp1, CREB, and CpG island methylation</article-title><source>J Androl</source><year>2009</year><volume>30</volume><issue>2</issue><fpage>157</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.2164/jandrol.108.005785</pub-id><?supplied-pmid 18930904?><pub-id pub-id-type="pmid">18930904</pub-id></element-citation></ref><ref id="CR56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanlan</surname><given-names>MJ</given-names></name><name><surname>Gure</surname><given-names>AO</given-names></name><name><surname>Jungbluth</surname><given-names>AA</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name></person-group><article-title>Cancer/testis antigens: an expanding family of targets for cancer immunotherapy</article-title><source>Immunol Rev</source><year>2002</year><volume>188</volume><issue>1</issue><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065X.2002.18803.x</pub-id><?supplied-pmid 12445278?><pub-id pub-id-type="pmid">12445278</pub-id></element-citation></ref><ref id="CR57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gevaert</surname><given-names>O</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Plevritis</surname><given-names>SK</given-names></name></person-group><article-title>Pancancer analysis of DNA methylation-driven genees using MethylMix</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0579-8</pub-id><?supplied-pmid 25631659?><pub-id pub-id-type="pmid">25631659</pub-id></element-citation></ref><ref id="CR58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilkes</surname><given-names>DM</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Wirtz</surname><given-names>D</given-names></name></person-group><article-title>Hypoxia and the extracellular matrix: drivers of tumour metastasis</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>141</volume><issue>6</issue><fpage>430</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nrc3726</pub-id><pub-id pub-id-type="pmid">24827502</pub-id></element-citation></ref><ref id="CR59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>The extracellular matrix: a dynamic niche in cancer progression</article-title><source>J Cell Biol</source><year>2012</year><volume>196</volume><issue>4</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1083/jcb.201102147</pub-id><?supplied-pmid 22351925?><pub-id pub-id-type="pmid">22351925</pub-id></element-citation></ref><ref id="CR60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendas</surname><given-names>G</given-names></name><name><surname>Borsig</surname><given-names>L</given-names></name></person-group><article-title>Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins</article-title><source>Int J Cell Biol</source><year>2012</year><volume>ID 676731</volume><fpage>10</fpage></element-citation></ref><ref id="CR61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okegawa</surname><given-names>T</given-names></name><name><surname>Pong</surname><given-names>R</given-names></name><name><surname>Hsieh</surname><given-names>J</given-names></name></person-group><article-title>The role of cell adhesion molecule in cancer progression and its application in cancer therapy</article-title><source>Acta Biochim Pol</source><year>2004</year><volume>51</volume><issue>2</issue><fpage>445</fpage><lpage>57</lpage><?supplied-pmid 15218541?><pub-id pub-id-type="pmid">15218541</pub-id></element-citation></ref><ref id="CR62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibikova</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>B</given-names></name><name><surname>Tsan</surname><given-names>C</given-names></name><name><surname>Ho</surname><given-names>V</given-names></name><name><surname>Klotzle</surname><given-names>B</given-names></name><name><surname>Le</surname><given-names>JM</given-names></name><etal/></person-group><article-title>High density DNA methylation array with single CpG site resolution</article-title><source>Genomics</source><year>2011</year><volume>98</volume><issue>4</issue><fpage>288</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2011.07.007</pub-id><?supplied-pmid 21839163?><pub-id pub-id-type="pmid">21839163</pub-id></element-citation></ref><ref id="CR63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Ladd-Acosta</surname><given-names>C</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Montano</surname><given-names>C</given-names></name><name><surname>Onyango</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><issue>2</issue><fpage>178</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/ng.298</pub-id><?supplied-pmid 19151715?><pub-id pub-id-type="pmid">19151715</pub-id></element-citation></ref><ref id="CR64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Mccue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title><source>Nat Methods</source><year>2008</year><volume>5</volume><issue>7</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id><pub-id pub-id-type="pmid">18175409</pub-id></element-citation></ref><ref id="CR65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>Regression shrinkage and selection via the lasso</article-title><source>J R Stat Soc</source><year>1996</year><volume>58</volume><issue>1</issue><fpage>267</fpage><lpage>88</lpage></element-citation></ref><ref id="CR66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meier</surname><given-names>D</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observation</article-title><source>J Am Statist</source><year>1958</year><volume>58</volume><fpage>457</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id></element-citation></ref><ref id="CR67"><label>67</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name></person-group><source>Analysis of Survival Data</source><year>1984</year><publisher-loc>London</publisher-loc><publisher-name>Chapman &#x00026; Hall/CRC Monographs on Statistics &#x00026; Applied Probability, Taylor &#x00026; Francis</publisher-name></element-citation></ref></ref-list></back></article>